ReviewJournal of mammary gland biology and neoplasia2001
The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis.
Review in Journal of mammary gland biology and neoplasia, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 177 citations in OpenAlex.
- Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.British journal of cancer · 2007Pooled it
- Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients.British journal of cancer · 2004Trial
- In vivo and in silico approaches for evaluating nerolidol-β-cyclodextrin nanoparticles: Antioxidant potential and hormonal modulation in DMBA-induced mammary carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Clinical importance of serum miRNA levels in breast cancer patients.Discover oncology · 2024Article
- American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: Summary for Clinicians.European journal of breast health · 2021Review
- Article
- Cancer biomarker profiling using nanozyme containing iron oxide loaded with gold particles.Journal of the Royal Society, Interface · 2020Article
- Development of a risk-stratification scoring system for predicting lymphovascular invasion in breast cancer.BMC cancer · 2020Article
- Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo.Breast cancer research : BCR · 2019Article
- Why Has Breast Cancer Screening Failed to Decrease the Incidence of de Novo Stage IV Disease?Cancers · 2019Article
- HER2-mediated GLI2 stabilization promotes anoikis resistance and metastasis of breast cancer cells.Cancer letters · 2019Article
- Expression of HER2/c-erbB-2, EGFR Protein in Gastric Carcinoma and its Clinical Significance.Open life sciences · 2019Article
- Temporal Efficacy of a Sulforaphane-Based Broccoli Sprout Diet in Prevention of Breast Cancer through Modulation of Epigenetic Mechanisms.Cancer prevention research (Philadelphia, Pa.) · 2018Article
- Novel cancer cell lines derived from primary breast tumors in Chinese patients.American journal of translational research · 2018Article
- Breast cancers withOncology letters · 2017Article
- Evaluation of prognostic factors and survival rates in malignant feline mammary gland neoplasms.Journal of feline medicine and surgery · 2016Article
- Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells.Oncogene · 2016Article
- FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics.Oncology letters · 2016Article
- Overcoming Resistance to Endocrine Therapy in Breast Cancer: New Approaches to a Nagging Problem.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2016Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene amplification and/or overexpression of the c-erbB-2/HER2/neu tyrosine kinase are linked with poor prognosis in breast cancer. This is manifest in shorter disease-free intervals, increased risk of metastasis, and resistance to many types of therapy. The molecular mechanisms and signaling circuitry underlying these phenomena are now being elucidated. c-erbB-2, although having no known soluble ligand, is transactivated by heterodimerization with other family members (EGFR, c-erbB-3, c-erbB-4). Receptor activation potentiates tumor cell motility, protease secretion and invasion, and also modulates cell cycle checkpoint function, DNA repair, and apoptotic responses. Since it is expressed at low levels in normal adult tissues, c-erbB-2 is an ideal target for therapy. There is reason for optimism that agents targeting c-erbB-2 signaling will have profound and selective effects in breast cancer, either as single agents or more likely in combination with other therapeutic agents, to enhance their potency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.